Enzymotec (ENZY) Q1 EPS Outpaces Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results
May 19, 2016 7:30 AM EDTReports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash FlowÂ
VAYA Pharma Generates Record Net Revenues of $3.1 Million
MIGDAL HA'EMEQ, Israel, May 19, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, Â manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the first quarter ended March 31, 2016.
First Quarter 2016 Financial Highlights
First quarter net revenues increased 23.6% and 5.3% to $14.0 million, compared to the first quarter of 2015 and the fourth... More